What AMPLY Discovery does

AMPLY Discovery is a Belfast-based private biotech that applies machine learning and synthetic biology to discover first-in-class therapeutics by mining the non-coding "dark genome" - the 98% of the human genome largely ignored by traditional drug discovery. The company was spun out of Queen's University Belfast and operates an integrated discovery platform centered on TALON, a stack of six specialized ML engines (PREDICT, VALIDATE, RETRAIN) that span target identification to molecule design. Its distinguishing architectural choice is LabCycle, a continuous closed loop between computational prediction and iterative wet-lab validation, supported by translational hubs in Belfast and London. The company pursues four pre-clinical programs: aerosolised antimicrobial peptides for multidrug-resistant tuberculosis and inhaled peptides for cystic fibrosis-associated lung infections, plus long non-coding RNA-targeting oligonucleotide programs in triple-negative breast cancer (at In Vitro POC) and acute myeloid leukemia.

AMPLY's business model is B2B licensing and partnership-based. The primary customer segment is biopharmaceutical partners seeking differentiated, experimentally validated therapeutic targets in oncology and infectious disease, with assets licensed at defined value-creation milestones. The company does not develop or commercialize drugs internally; rather, it monetizes discovery output through partnerships. Its only publicly disclosed commercial relationship to date is a February 2026 strategic investment and oncology partnership with South Korea's Keeps Biomed, which acquired a 5.14% equity stake alongside a Right of First Refusal for anticancer programs. AMPLY has secured approximately $5.2 million in cumulative funding across Innovate UK and Innosuisse grants, a Techstars accelerator placement, and a seed round led by Twin Path Ventures. The company is pre-revenue and remains at an early stage of pipeline and commercial development.

Technically, AMPLY's differentiation rests on three pillars: (1) the dark-genome focus, which opens target space inaccessible to protein-coding-focused competitors; (2) the TALON platform's closed-loop architecture, which combines ML-driven prediction with mandatory empirical validation rather than relying solely on in silico outputs; and (3) the HALLUX engine, a domain-specialized module for identifying lncRNA dependencies in cancer. The leadership team combines over 100 years of biotech and computational biology experience, and the February 2026 appointment of Dr. Oliver Rausch as CSO (from Storm Therapeutics) signals deepening oncology expertise. The strategic risk is concentration around a single partner and absence of disclosed independent validation of AI accuracy; the upside is that the closed-loop architecture provides a credible mechanism to convert AI predictions into licensable, experimentally grounded assets in a target space competitors have largely ignored.

Name

AMPLY Discovery

Legal name

AMPLY Discovery Limited

Website

https://amplydiscovery.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

AMPLY Discovery is a Belfast-based biotech using AI/ML and synthetic biology to discover first-in-class therapeutics from the non-coding "dark genome," licensing validated targets to biopharmaceutical partners at defined value-creation milestones.

Ownership category

akta.pro rank

Product category

AI drug discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• AI drug discovery
• Dark genome therapeutics
• Oncology pipeline programs
• Antimicrobial peptide therapeutics
• Machine learning biology

Headquarters

HQ city

Belfast

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations

Distribution channels1 record

Marketing channels3 records

Core offering

AMPLY Discovery uses its TALON platform—a stack of six machine-learning engines—and LabCycle wet-lab validation to mine multi-omic datasets from the non-coding "dark genome" (98% of the human genome) and identify first-in-class therapeutic targets. The company develops and licenses peptide and oligonucleotide therapeutic candidates across four pipeline programmes: antimicrobial peptides for multidrug-resistant tuberculosis and cystic-fibrosis lung infections, and lncRNA-targeting oligonucleotides for triple-negative breast cancer and acute myeloid leukaemia.

Product overview

AMPLY Discovery is a UK biotech developing first-in-class therapeutics by targeting the 98% of the genome largely ignored by drug developers. The core offering consists of the TALON platform, an end-to-end stack of six ML engines for target discovery, and the LabCycle validation system enabling continuous closed-loop iteration between computational prediction and wet-lab testing. The pipeline comprises four therapeutic programmes: two antimicrobial-peptide programmes targeting drug-resistant respiratory infections (MDR Tuberculosis and CF Lung Infections) and two long non-coding RNA oligonucleotide programmes against hard-to-treat oncology indications (Triple-Negative Breast Cancer and Acute Myeloid Leukaemia).

Differentiator

Problem solved

Functional benefit

Products and services

• TALON Platform End-to-end integrated machine-learning stack of six specialised AI engines (PREDICT, VALIDATE, RETRAIN) for discovering therapeutic targets in the non-coding dark genome, covering target identification, molecule design and bench prioritization for partner licensing.
• LabCycle Continuous closed loop between silicon (computational prediction) and bench (wet-lab validation) operating at world-class translational hubs in Belfast and London, used to experimentally validate AI-generated therapeutic candidates for licensing partners.
• MDR Tuberculosis Programme Aerosolised antimicrobial peptide therapeutic for multidrug-resistant tuberculosis, targeting critical care with low resistance liability; licensable asset for biopharma partners, currently in In Vivo preclinical stage.
• CF Lung Infections Programme Inhaled peptide therapeutic targeting cystic fibrosis-associated lung infections caused by Pseudomonas aeruginosa and resistant Staphylococcus species, delivering multi-mechanism activity at high local concentration; licensable to biopharma partners.
• Triple-Negative Breast Cancer Programme Long non-coding RNA (lncRNA)-targeting oligonucleotide programme for triple-negative breast cancer that silences cancer-specific dependencies surfaced in the dark genome; licensable to biopharma partners, currently at In Vitro Proof-of-Concept stage.
• Acute Myeloid Leukaemia Programme Long non-coding RNA (lncRNA) oligonucleotide programme targeting subtype-specific dependencies in acute myeloid leukaemia, opening new therapeutic windows where 5-year survival is below 30% in older adults; licensable to biopharma partners.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind-derived AI to pharmaceutical R&D. Functions as a broad incumbent in the AI-discovery space with substantially greater capital, computational infrastructure, and pharma partnerships than AMPLY, but operating in the same target-identification and molecule-design category.

Direct peers

• Exscientia: AI-driven precision medicine company using its Centaur platform to design and develop novel drug candidates, with multiple pharma partnerships and clinical-stage assets. Comparable in its pharma partnership-led business model and AI-native approach to small-molecule and increasingly biologic drug design.
• Insilico Medicine: AI-driven drug discovery company with end-to-end platforms spanning target identification, molecule design, and clinical development. Comparable in its full-stack approach combining AI engines with wet-lab validation, and in its focus on generating first-in-class candidates for partnering.
• BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML to identify novel targets and develop therapeutics, with a similar business model of generating licensable assets for pharmaceutical partners. Highly relevant given its emphasis on target identification from previously unexplored biological relationships.
• Insitro: Machine learning-driven drug discovery company building predictive models from large-scale biological data to accelerate target identification and therapeutic development. Comparable in its ML-plus-wet-lab hybrid approach and focus on unlocking novel therapeutic targets via data-driven approaches.
• Lantern Pharma: AI-driven oncology drug development company using its RADR platform to identify responders, repurpose drugs, and discover new compounds. Comparable as an AI-discovery peer operating a hybrid computational-experimental pipeline focused on oncology indications and licensing assets to larger partners.
• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput wet-lab biology with machine learning to identify novel therapeutic targets and candidates. Most directly comparable to AMPLY's TALON platform philosophy of integrating ML prediction with experimental validation, though operating at far greater scale across multiple therapeutic areas.
• Verge Genomics: AI-driven drug discovery company using human genomics and ML to identify novel therapeutic targets, particularly in neuroscience and rare diseases. Comparable as an early-to-mid stage AI-discovery peer employing a data-first approach to target identification and partnering with larger pharma.

Emerging players

• Owkin: AI-biotech combining multimodal patient data with ML to discover and develop therapeutics, particularly in oncology. Comparable as an emerging ML-driven discovery company that integrates biological data, ML, and experimental validation to generate licensable therapeutic assets.
• Storm Therapeutics: UK-based biotech focused on RNA-modulating therapeutics for oncology, particularly targeting RNA-modifying enzymes. Highly relevant adjacent peer given that AMPLY's new CSO joined from Storm and AMPLY's HALLUX engine similarly focuses on RNA biology (lncRNAs) for cancer indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amply-discovery

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMPLY Discovery